Jerusalem, 5 March, 2026 (TPS-IL) — Israel-based Matricelf Ltd., a biotechnology company developing personalized regenerative therapies, announced promising results from advanced RNA sequencing analyses of its spinal cord implant, supporting a strong safety profile for future clinical trials. Tests on four implant batches showed all cells were in a stable, non-dividing state, reducing risks of uncontrolled growth or unintended tissue formation.
Matricelf’s technology combines a patient’s own stem cells with a proprietary hydrogel scaffold to create a personalized neural tissue implant designed to repair spinal cord injuries. The company said these findings mark a key milestone in its preclinical development and strengthen the potential for safe human trials.